Introduction
Hyperuricemia and gout have become increasingly common in China. The prevalence of hyperuricemia among Chinese adults was 8.4% in [2009] [2010] . The high prevalence may be related to the changes in diet, alcohol, and intake of fructose-containing drinks, and an increase in the number of overweight and obese patients [1] . Xanthine oxidase inhibitors are the key medications in the long-term treatment of hyperuricemia. Allopurinol and febuxostat are two important xanthine oxidase inhibitors. Allopurinol is transformed into its active metabolite oxypurinol, which reversibly blocks xanthine oxidase, whereas febuxostat is a non-purine-selective inhibitor of xanthine oxidase [2] . Allopurinol is a common efficacious urate-lowering therapy, but it is associated with rare serious adverse drug reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) [3] . The human leukocyte antigen B allele HLA-B*5801 was reported to be a genetic marker for allopurinol-induced side effects [4, 5] . Strong associations between HLA-B*5801 and allopurinol-induced TEN/SJS were found in Hong Kong [6] , Korea [7] , and Thailand [8] . Genome-wide association study of SJS and TEN also confirmed that the HLA-B*5801 allele was associated with allopurinol-induced symptoms in Europe [9] . Screening genotypes of HLA-B*5801 before prescribing allopurinol offers the possibility of avoiding allopurinol-induced SJS/TEN.
Patients who are HLA-B*5801 carriers can be alternatively administered febuxostat. The clinical consideration is the cost of febuxosat as it is much higher than the administration of allopurinol in China. There is a paucity of evidence on the economic value of such testing as allopurinol is an affordable medication. Testing HLA-B*5801 before allopurinol management is cost-effective for Asians and African Americans, but not for Whites or Hispanics in the USA [10] . It was also shown to be a highly potential cost-effective intervention in Thailand [11] . The Chinese Han population is a high-risk group for the side effects of allopurinol [12] ; in this retrospective report, we screened HLA-B*5801 in 253 hyperuricemia and gout patients in a Han population in the Shenzhen area of China. We determined the HLA-B*5801 frequency and investigated the clinical management of medications. We also analyzed the cost-effectiveness of the screening HLA-B*5801 before the administration of allopurinol in the patient groups.
Patients and methods
This study was approved by the Ethics Committee of the First Affiliated Hospital of Shenzhen University, Shenzhen, China, and was carried out in accordance with the approved guidelines and regulations. Informed written consent was obtained from the parents of all patients.
Patients
We recruited 253 patients with hyperuricemia or gout from April 2016 to April 2017 in the First Affiliated Hospital of Shenzhen University. The average age of the patients was 48.47 15.13 years. There were 206 (81.4%) male patients and 47 (18.6%) female patients. Clinical information such as uric acid, corrected creatinine clearance, estimated glomerular filtration rate (eGFR), the abnormality in stroke, hepatic adipose infiltration, and Somatom definition was obtained in the central laboratory and related departments in the hospital following the standard protocols for each measurement. All the patients were examined in the outpatient department and the records were retained for the analysis.
Genotyping
Blood from the patients was collected and DNAs were extracted following the protocols of the Blood DNA mini Extraction Kit of the HYK Gene Technology Company Limited (Shenzhen, China). The HLA-B*5801 allele was genotyped using a CFX96 nucleic acid amplification fluorescence detector (M-A1-048; Pharmigene Inc., New Taipei City, Taiwan); the PCR method combined with fluorescent dye amplification technology was used according to the manufacturer's protocols. Briefly, for the RT-PCR and SYBR Green-based detection method, each sample requires only two PCR runs for the detection of HLA-B*5801 and the internal control. Analysis is based on Ct values [13] . The HLA-B*5801 carrier was defined as genotypes for diplotypes HLA-B*5801/X and HLA-B*5801/HLA-B*5801 (X was indicated for any HLA-B genotype other than HLA-B*5801).
The records of medications for hyperuricemia and gout patients
We checked the records for medication usage for the 253 hyperuricemia and gout patients. The results were verified by the consultants who treated these patients clinically.
The analysis of cost-effectiveness for screening of HLA-B*5801
At the time of the research, the cost of screening of HLA-B*5801 was 800 Renminbi (RMB) yuan (the official currency of China). Allopurinol was 0.5 RMB yuan for 0.1 g/tablet per tablet and febuxostat was 20 RMB yuan for 40 mg/tablet per tablet.
Model 1 represented the initial dosages of allopurinol 100 mg/day and febuxostat 40 mg/day; model 2 represented maximum dosages of allopurinol 600 mg/day and febuxostat 80 mg/day. Cost (y 1 ) = time × daily spending on allopurinol + test fee of HLA-B*5801.
Cost (y 2 ) = time × daily spending on febuxostat.
We also recruited 253 patients to calculate the possible cost for the management of hyperuricemia.
Model 3 represented the initial dose of allopurinol 100 mg/day and febuxostat 40 mg/day; model 4 represented the maximum dose of allopurinol 600 mg/day and febuxostat 80 mg/day.
In model 3 and model 4, we compared the cost of using febuxostat without HLA-B*5801 screening and the cost with HLA-B*5801 screening. We defined the administration of medications as standardized usage according to the results of the screening. If HLA-B*5801 was negative, allopurinol would be used for the treatment; if HLA-B*5801 was positive, febuxostat would be used for the treatment. The cost of standardized usage of medications included: A: febuxostat cost = [febuxostat amount (y 2 ) + gene test fee] × all × gene positive detection rate and B: allopurinol cost = [allopurinol amount (y 1 ) + gene test fee] × all × gene negative detection rate. The cost without screening HLA-B*5801 and using febuxostat was C: febuxostat cost = daily spending × time.
Statistical methods
Data were analyzed with SPSS 17.0 software (SPSS Inc., Chicago, Illinois, USA). The measurement data of the normal distribution were expressed as mean SD, and the t-test was used to compare two groups. Wilcoxon Mann-Whitney tests were applied. Count data were expressed as rate (%),comparison between groups was performed using the χ 2 -test, and comparison between multiple groups was performed using one-way analysis of variance. A P value less than 0.05 was considered to be statistically significant.
Results

HLA-B* genotype results and patient clinical characteristics
In 253 patients, we identified 30 HLA-B*5801 carriers; the HLA-B*5801 positive rate was 11.9% in the total screening patients. In the HLA-B*5801 carrier group, 30% of patients were women, whereas in the HLA-B*5801 noncarrier group, 17% of patients were women. Only age showed a statistically significant difference as the carriers were on average older than the noncarrier group (54.3 14.3 and 47.7 15.1 respectively, P = 0.024). There was no difference in uric acid, corrected creatinine clearance, eGFR, abnormality in stroke screening, hepatic adipose infiltration, stones in urinary tract, and Somatom definition positivity between the two groups ( Table 1 ).
The treatment records of the patients with the completed clinical information
A total of 86 patients were found to have incomplete clinical data (39 cases did not have data on the history of gout, 44 cases did not have 24-h uric acid values, and three cases did not have eGFR values). These patients were excluded from the analysis. A total of 167 cases had complete clinical information. Group A (both allopurinol and febuxostat could be used patients from wealthy families could afford to be treated with febuxostat directly) included 120 patients with eGFR more than 30 ml/min/1.73 m 2 . These patients had a history of gout, urolithiasis positivity, and reduced uric acid excretion, increased formation of uric acid, and asymptomatic hyperuricemia. Group B (a noncompetitive inhibitor of xanthine oxidase benzbromarone or febuxostat could be used) included 47 cases, with a total of 41 patients having asymptomatic hyperuricemia and reduced uric acid excretion (no kidney stone and eGFR > 20 ml/min/ 1.73 m 2 ) and six patients with eGFR less than 30 ml/min/ 1.73 m 2 . The patients had a history of gout, urolithiasis positivity, and without color ultrascan in the type of reduced uric acid excretion, increased formation of uric acid, and asymptomatic hyperuricemia. In group A, 15% of patients (18/120) were carriers of HLA-B*5801 and in group B, 12.8% of patients (6/47) were carriers of HLA-B*5801. There was no difference in the HLA-B*5801 carriers between two groups. Details of the groups' treatment are shown in Fig. 1 .
The clinical management of allopurinol in HLA-B*5801-negative and HLA-B*5801-positive groups
We then investigated how the medications were administered in patients and obtained information on 243 patients of a total of 253 patients (Table 2) . There were 214 patients with HLA-B*5801-negative genotypes. Of these, a total of 44 patients were managed with allopurinol and 29 (13.6%) patients were managed with febuxostat. Nineteen patients were managed with benzbromarone, a uricosuric agent and noncompetitive inhibitor of xanthine oxidase. Thirty-eight patients were managed with other medications such as NSAIDs. The rest of the 84 patients were managed by diet control. For 29 patients with HLA-B*5801-positive genotypes, one patient was treated with allopurinol, seven patients were treated with febuxostat, two patients were treated with benzbromarone, and five patients were managed with other medication. The rest of the 14 patients were managed by diet control. It was clear there the management was inappropriate in both groups as for the HLA-B*5801-negative group, the febuxostat users could change to be treated with allopurinol and for the HLA-B*5801 positive group, the allopurinol user should change to be treated with febuxostat. The results indicated that gene screening for HLA-B*5801 would lead to the correct use of allopurinol and febuxostat in the clinical management of hyperuricemia patients.
Cost-effectiveness analysis of the screening of HLA-B*5801 in different models
In model 1, allopurinol and febuxostat were used at the lowest dosages. The cost would be higher in the first 42 days for the allopurinol group with testing for the genotype of HLA-B*5801. After 42 days, it would significantly save the cost for the patients with the genotype screening as allopurinol is correctly administered. There would be a saving of 2749 yuan per patient for half a year and 6317.5 yuan for 1 year of treatment.
In model 2, allopurinol and febuxostat were used at the highest dosages. The cost would be higher in the first 22 days for allopurinol with testing for the genotype of HLA-B*5801. After 22 days, there would be significant cost savings for the patients with the genotype screening. There would be a saving of 5934 yuan per patient for half a year and a saving of 12 705 yuan for 1 year of treatment.
In model 3, the costs of allopurinol and febuxostat at the lowest dosages in all 253 patients were calculated. The costs of standard medication would be higher in the first 47 days for the cost of using febuxostat only. After 47 days, it would significantly save the cost for the patients with the genotype screening as allopurinol is correctly administered. There would a saving of 588 647.3 yuan for half a year and a saving of 1 384 040.9 yuan for 1 year of treatment.
In model 4, allopurinol and febuxostat were used at the highest dosages in all 253 patients. The standard medication cost would be higher in the first 25 days for the cost of direct using febuxostat only. After 25 days, it would significantly save the cost for the patients with the genotype screening as allopurinol is correctly administered. It would result in the saving of 1 298 561.5 yuan for half a year and a saving of 2 807 770.0 yuan for 1 year of treatment.
Using allopurinol directly without screening HLA-B*5801, the cost for the treatment of all 253 patients could be even higher as severe skin allergies and other HLA-B*5801 and hyperuricemia patients Cheng et al. 119
severe conditions would require much more resources for treatment [14] .
The decision of clinical management with genetics and without genetics screening of HLA-B*5801 is shown in Fig. 2 . The models and the results of the costeffectiveness of the genotyping of HLA-B*5801 are shown in Fig. 3 and Table 3 .
Discussion
Shenzhen is one of China's economically developed coastal areas with a high incidence of gout. In this report, we found that in Shenzhen, 11.9% of hyperuricemia and gout patients were carriers of HLA-B*5801, which was slightly higher than that of the Chinese population in Taiwan, where HLA-B*5801 was screened routinely (10.4%) [12, 15] . With the rapidly industrialized development in China, the number of hyperuricemia and gout patients has increased yearly because of changes in the diet. The patients became younger. Allopurinol as a firstline medication for uric acid treatment has been used in China for many years. The medication can cause severe skin allergies, and can even lead to death. The human leukocyte antigen (HLA) B allele HLA-B*5801 has been reported to be a genetic marker for allopurinol-related diseases [4, 13, 16, 17] . HLA-B*5801 carriers were at a higher risk of developing SJS/TEN after management with allopurinol [5, 8, 18] . The prevalence of HLA-B*5801 carriers varies by race, ethnicity, and geographic regions. Asian populations have higher HLA-B*5801carriers. In the USA, Whites and Hispanics have a low prevalence (< 1%); the prevalence of HLA-B*5801 is higher in Africa Americans (3.8%) and Asians (7.4%) [12, 19] . The 2012 American College of Rheumatology guidelines recommended screening HLA-B*5801 before the initiation of allopurinol treatment in high-risk patients. In China, there is a lack of such guidelines in the medical community for the usage of allopurinol. In our screening of Fig. 1 The decision of clinical management of hyperuricemia patients. Patients from group A were treated with allopurinol and patients from group B were treated without allopurinol. The medication for group b was febuxostate or benzbromarone for hyperuricemia. eGFR, estimated glomerular filtration rate; HUA, hyperuricemia. HLA-B*5801 in a total of 253 cases, the carrier rate was 11.9% and was higher than that in the Han ethical group in the USA; this indicates that the screening of HLA-B*5801 is necessary and that allopurinol management is useful.
In addition, the study showed that 15% of the patients in the allopurinol-treatment group (A) were carriers of HLA-B*5801 and 12.8% of the patients in the group without allopurinol treatment (B) were carriers of HLA-B*5801; there was no statistical difference between the two groups. Therefore, patients with hyperuricemia and gout cannot be treated randomly by allopurinol as clinical characteristics are not reliable for the indications of the choice of medication. In 2008 and 2009, the European Medicines Agency and the Food and Drug Administration approved febuxostat, which is safer than allopurinol in patients with mild to moderate renal impairment and liver damage. Patients do not have to adjust their doses, but the medication is more expensive and places a financial burden on families [20] . In our study, the HLA-B*5801 carriers were older and older age was a risk factor for allopurinol allergy syndrome [21, 22] .
In 2005, a strong association between HLA-B*5801 and allopurinol-induced adverse reactions was reported for the first time in a Han Chinese population. All patients with allopurinol-induced adverse reactions carried HLA-B*5801 [4] . This association was later confirmed in Thai [8] , Korean [7] , European [23, 24] , and Japanese populations [25, 26] . A potentially fast screening method was developed as an ideal tool to genotype the HLA-B* 5801 allele [27] . The association observed was not so strong in European and Japanese patients, which was probably because of the different prevalences of this HLA allele in the general population, which is high in Han Chinese patients (10-15%) and low (1-2%) in European and Japanese patients [16, 23, 28] . In a report of 48 patients with allopurinol-severe cutaneous adverse reactions (SCAR) and 138 allopurinol-tolerant controls, the HLA-B* 5801 allele was strongly associated with allopurinol-SCAR. Poor renal function was associated significantly with the delayed clearance of plasma oxypurinol and increased the risk of allopurinol-SCAR and impaired renal function, and increased plasma levels of oxypurinol and granulysin correlated with the poor prognosis of allopurinol-SCAR. An early intervention to increase the clearance of plasma oxypurinol may improve the prognosis of allopurinol-SCAR [29] . In a study in Singapore, HLA-B*5801-guided urate-lowering therapy selection or enhanced safety program was not costeffective [30] . In a report from Australia, there was a clear influence of positivity for HLA-B*5801 on the phenotypical response to allopurinol exposure in a Han family. HLA-B*5801 should be used to screen Han Chinese patients for the risk of allopurinol-induced SJS before initiation of the drug, particularly if a family member has experienced this serious adverse reaction [31] . In a meta-analysis, HLA-B*5801 was found to be associated with allopurinol-induced TEN/SJS in European and Japanese populations, but only had a 50-60% sensitivity (pooled sensitivity 56%) compared with the 80-100% sensitivity (pooled sensitivity 97%) observed in Korean, Thai, Sardinia Italian, and Han Chinese populations [32] . Two cases of allopurinolinduced drug eruptions in patients carrying HLA-B*5801 were reported in mainland China [33] .
Febuxostat was more effective than allopurinol in Hypothesis 0 for model 1 and 2, the cost for genotyping screening and allopurinol more than the cost for febuxostat. Hypothesis 1 for model 1 and model 2, the cost for genotyping screening and allopurinol less than the cost for febuxostat. The regression models accepted hypothesis 1 for model 1 and model 2. Hypothesis 0 for model 3 and model 4, the cost routine genotyping screen more than the cost for direct usages for medication. Hypothesis 1 for model 3 and model 4, the cost routine genotyping screen less than the cost for direct usages for medication. The regression models accepted hypothesis 1 for model 3 and model 4.
reducing the serum urate levels of Han Chinese patients with gout or tophaceous gout who were HLA-B*5801 negative, without causing any serious skin reactions [34] .
For patients with hyperuricemia or gout who need longterm treatment, use of allopurinol and screening of the HLA-B*5801 allele are cost-effective compared with management with febuxostat. Routine screening of HLA-B*5801 not only prevents severe cutaneous anaphylaxis caused by allopurinol but also reduces mortality during the treatment process. Our regression models of the cost confirmed the advantages of screening the genetic allele before making the decisions on the medications to be used. The cost-effectiveness analysis provided convincing evidence to reduce patient's financial burden, particularly for the long-term management of hyperuricemia. Therefore, we strongly believe that the HLA-B*5801 allele should be screened routinely in hyperuricemia and gout patients in the Han population in China.
Conclusion
This report clearly indicates the importance of screening HLA-B*5801 in South China. The prevalence of the HLA-B*5801 in hyperuricemia or gout patients was slightly higher in the Han population than that in other Asian populations. The screening will not only help the appropriative use of allopurinol but also have cost-effectiveness for treatments of hyperuricemia and gout patients. The screening also provides the prevention of vital side effects of allopurinol in the treatments, as allopurinol is one of the important reasons for SJS or TEN [3] . So far, China's latest guidelines for hyperuricemia and gout have not required screening of HLA-B*5801 before taking allopurinol. Our results indicated that screening the genotype had more economic value and it reduced unnecessary financial burden on patients. The limitation of this study was the small sample size and lack of the information on the side effects of allopurinol because of the short treatment course, but it provides strong evidence to support to screening of HLA-B*5801 in the Chinese population for appropriate management with allopurinol.
